CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Correction of a pathogenic gene mutation in human embryos A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration Developing and Testing a Personalized, Evidence-Based, Shared Decision-Making Tool for Stent Selection in Percutaneous Coronary Intervention Using a Pre-Post Study Design Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond Hs-cTroponins for the prediction of recurrent cardiovascular events in patients with established CHD - A comparative analysis from the KAROLA study How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD

Editorial2018 Jan 6;391(10115):3-4.

JOURNAL:Lancet. Article Link

Last nail in the coffin for PCI in stable angina?

Brown DL, Redberg RF. Keywords: comment; stable angina; PCI

ABSTRACT


Interventional cardiology began in Switzerland in 1977, when Andreas Gruentzig performed the first successful percutaneous transluminal coronary angioplasty (PTCA) on a 38-year-old man with angina and a focal proximal stenosis of the left anterior descending coronary artery. Despite numerous subsequent randomised trials and meta-analyses of these trials, which have shown no reduction in death or myocardial infarction,1 the use of percutaneous coronary intervention (PCI) has grown exponentially. Some of this growth was driven by data from clinical trials suggesting that PCI was more effective in relieving angina than medical therapy alone.